Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, is pleased to announce that they will be holding an Investors Webinar to discuss the positive findings of their Phase 2b clinical study testing XF-73 nasal gel as a novel product for the prevention of post-surgical infections.
The event will take place at 3.30pm, Tuesday the 30th March 2021.
The online presentation is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end.
Register here:
